<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02567045</url>
  </required_header>
  <id_info>
    <org_study_id>Colorectal cancer screening</org_study_id>
    <nct_id>NCT02567045</nct_id>
  </id_info>
  <brief_title>Uptake to Colorectal Cancer Screening in Familial-risk Population</brief_title>
  <official_title>Uptake to Colorectal Cancer Screening in Familiar-risk Population: A Randomized Controlled Trial Comparing Immunochemical Fecal Occult Blood Test With Colonoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario de Canarias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario de Canarias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, controlled, randomized phase III study to compare participation rate
      with two screening rounds of fecal occult blood test (FIT) versus one-time screening
      colonoscopy in first degree relatives (FDR) of patients diagnosed of colorectal cancer (CRC).

      The hypothesis of the study is that annual FIT uptake and colonoscopy when a positive test is
      higher than that of straightforward colonoscopy. Assuming an uptake of 0.50 for colonoscopy
      and 0.60 for FIT, a Type I error (alpha) of 5% and a power of 90%, 538 FDRs will be necessary
      to include in each group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicenter, controlled, randomized phase III study to compare participation rate
      with two screening rounds of FIT versus one-time screening colonoscopy in FDR of patients
      diagnosed of CRC.

      The recruitment process will be programmed through the index case, that will be interviewed
      to obtain their CRC family history. FDR will be contacted in order to make an appointment in
      the High-risk CRC Clinic of the participant centers. Randomization will be performed before
      signing the informed consent to avoid selection bias. A researcher will be responsible to
      provide detailed information about the study and getting the informed consent. In case of
      willingness to participate in the study, the FDR will be randomized to one of the following
      arms: A) One-time colonoscopy; B) annual FIT for two screening rounds and a colonoscopy in
      case of a positive FIT (cut-off = 10 μg Hemoglobin/g feces). Screening uptake will be defined
      as the percentage of FDR who participate at least in one of the two FIT screening round in
      the FIT group or who undergo colonoscopy in the other group. Screening uptake will be
      calculated under the assumption of intention to screen analysis.

      The hypothesis of the study is that annual FIT uptake and colonoscopy when a positive test is
      higher than that of straightforward colonoscopy. Assuming an uptake of 0.50 for colonoscopy
      and 0.60 for FIT, a Type I error (alpha) of 5% and a power of 90%, 538 FDRs will be necessary
      to include in each group.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participants were randomized to either colonoscopy or faecal occult blood test</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who participate in each screening arm</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy measure: QALYs (Quality adjusted life years).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs measure: cost (euros) of the procedures associated with each screening strategy and treatment of advanced neoplastic lesions</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1076</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Screening Uptake of Colonoscopy and FIT</condition>
  <arm_group>
    <arm_group_label>Fecal occult blood testing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Annual FIT and colonoscopy in case of a positive test. Fecal occult blood testing: annual FIT (two rounds) without diet restriction, one stool sample. Positive cut-off = 10 μg Hemoglobin/g feces.
Colonoscopy will be performed in case of a positive FIT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>one-time Colonoscopy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One-time Colonoscopy with sedation</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>annual FIT and colonoscopy in case of a positive test</intervention_name>
    <description>FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.</description>
    <arm_group_label>Fecal occult blood testing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colonoscopy with sedation</intervention_name>
    <description>One-time Colonoscopy with sedation.</description>
    <arm_group_label>Fecal occult blood testing</arm_group_label>
    <arm_group_label>one-time Colonoscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. FDR with a case index meeting the following conditions: at least one case index &lt; 60
             years at diagnosis of the CCR;

          2. having ≥ 2 FDRs with CRC regardless the age of the case index at diagnosis;

          3. having a sibling with CRC;

          4. age &lt;75 years.

        Exclusion Criteria:

          1. past CRC screening;

          2. inflammatory bowel disease or past history of colorectal neoplasia;

          3. Family history of hereditary CRC;

          4. Abdominal symptoms;

          5. Colectomy;

          6. Severe comorbidity leading to a poor prognosis (life expectancy &lt; 5 years);

          7. Refusal to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enrique Quintero, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario de Canarias</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Z. Gimeno, MD, PhD</last_name>
    <phone>+34922678039</phone>
    <email>antozeben@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Federico Sopeña Biarge</name>
      <address>
        <city>Zaragoza</city>
        <state>Aragón</state>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pilar Roncales Lazaro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cristina Alvarez Urturi, MD</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Alvarez Urtur, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maria Teresa Ocaña Bombardo</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María T Ocaña Bombardo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inés Castro Novo</name>
      <address>
        <city>Ourense</city>
        <state>Galicia</state>
        <zip>32005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Patricia Muñoz Garrrido</name>
      <address>
        <city>San Sebastián</city>
        <state>País Vasco, Gipuzcoa</state>
        <zip>20080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Muñoz Garrrido, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Digestive Service, Huc</name>
      <address>
        <city>La Laguna</city>
        <state>S/c de Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ENRIQUE QUINTERO, MD. PhD.</last_name>
      <phone>615553711</phone>
      <email>equintero@gmail.com</email>
    </contact>
    <investigator>
      <last_name>ENRIQUE QUINTERO, MD. PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Z Gimeno García, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Zaida Adrián de Ganzo, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David N Pérez, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marta Carrillo Palau, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>María Rodriguez Soler</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María Rodriguez Soler, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <results_reference>
    <citation>Quintero E, Carrillo M, Gimeno-García AZ, Hernández-Guerra M, Nicolás-Pérez D, Alonso-Abreu I, Díez-Fuentes ML, Abraira V. Equivalency of fecal immunochemical tests and colonoscopy in familial colorectal cancer screening. Gastroenterology. 2014 Nov;147(5):1021-30.e1; quiz e16-7. doi: 10.1053/j.gastro.2014.08.004. Epub 2014 Aug 13.</citation>
    <PMID>25127679</PMID>
  </results_reference>
  <results_reference>
    <citation>Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD, Hernández C, Jover R, Montalvo I, Arenas J, Laredo E, Hernández V, Iglesias F, Cid E, Zubizarreta R, Sala T, Ponce M, Andrés M, Teruel G, Peris A, Roncales MP, Polo-Tomás M, Bessa X, Ferrer-Armengou O, Grau J, Serradesanferm A, Ono A, Cruzado J, Pérez-Riquelme F, Alonso-Abreu I, de la Vega-Prieto M, Reyes-Melian JM, Cacho G, Díaz-Tasende J, Herreros-de-Tejada A, Poves C, Santander C, González-Navarro A; COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012 Feb 23;366(8):697-706. doi: 10.1056/NEJMoa1108895. Erratum in: N Engl J Med. 2016 May 12;374(19):1898.</citation>
    <PMID>22356323</PMID>
  </results_reference>
  <results_reference>
    <citation>Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):501-10. doi: 10.1097/CHI.0b013e31819c23ed.</citation>
    <PMID>19307987</PMID>
  </results_reference>
  <results_reference>
    <citation>Dove-Edwin I, Sasieni P, Adams J, Thomas HJ. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ. 2005 Nov 5;331(7524):1047. Epub 2005 Oct 21.</citation>
    <PMID>16243849</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunochemical fecal occult blood test</keyword>
  <keyword>Colonoscopy</keyword>
  <keyword>Screening uptake</keyword>
  <keyword>Screening participation</keyword>
  <keyword>Familiar risk</keyword>
  <keyword>Colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

